You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDesipramine
Accession NumberDB01151  (APRD00022, DB07682)
TypeSmall Molecule
GroupsApproved
DescriptionDesipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Desipramine exerts less anticholinergic and sedative side effects compared to tertiary amine TCAs, such as amitriptyline and clomipramine. Desipramine may be used to treat depression, neuropathic pain (unlabeled use), agitation and insomnia (unlabeled use) and attention-deficit hyperactivity disorder (unlabeled use).
Structure
Thumb
Synonyms
3-(10,11-DIHYDRO-5H-dibenzo[b,F]azepin-5-yl)-N-methylpropan-1-amine
5-(gamma-Methylaminopropyl)iminodibenzyl
5-(γ-methylaminopropyl)iminodibenzyl
Déméthylimipramine
Desipramin
Desipramina
Desipramine
Desipraminum
Desmethylimipramine
DMI
Monodemethylimipramine
N-(3-methylaminopropyl)iminobibenzyl
Norimipramine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Desipraminetablet100 mgoralAa Pharma Inc1996-12-31Not applicableCanada
Desipraminetablet75 mgoralAa Pharma Inc1996-12-31Not applicableCanada
Desipraminetablet10 mgoralAa Pharma Inc1996-12-31Not applicableCanada
Desipraminetablet50 mgoralAa Pharma Inc1996-12-31Not applicableCanada
Desipraminetablet25 mgoralAa Pharma Inc1996-12-31Not applicableCanada
Desipramine Hydrochloridetablet, sugar coated25 mg/1oralWinthrop U.S.2014-04-01Not applicableUs
Desipramine Hydrochloridetablet, sugar coated150 mg/1oralWinthrop U.S.2014-04-01Not applicableUs
Desipramine Hydrochloridetablet, sugar coated50 mg/1oralWinthrop U.S.2014-04-01Not applicableUs
Desipramine Hydrochloridetablet, sugar coated75 mg/1oralWinthrop U.S.2014-04-01Not applicableUs
Desipramine Hydrochloridetablet, sugar coated10 mg/1oralWinthrop U.S.2014-04-01Not applicableUs
Desipramine Hydrochloridetablet, sugar coated100 mg/1oralWinthrop U.S.2014-04-01Not applicableUs
Desipramine-10 - Tab 10mgtablet10 mgoralPro Doc Limitee1996-12-042010-07-13Canada
Desipramine-25 - Tab 25mgtablet25 mgoralPro Doc Limitee1997-04-302010-07-13Canada
Desipramine-50 - Tab 50mgtablet50 mgoralPro Doc Limitee1996-12-062010-07-13Canada
Desipramine-75 - Tab 75mgtablet75 mgoralPro Doc Limitee1997-02-272010-07-13Canada
Dom-desipramine Tablets - 25mgtablet25 mgoralDominion Pharmacal1996-12-31Not applicableCanada
Dom-desipramine Tablets - 50mgtablet50 mgoralDominion Pharmacal1996-12-31Not applicableCanada
Norpramintablet, sugar coated10 mg/1oralSanofi Aventis U.S. Llc1964-11-20Not applicableUs
Norpramintablet, sugar coated100 mg/1oralSanofi Aventis U.S. Llc1964-11-20Not applicableUs
Norpramintablet, sugar coated25 mg/1oralSanofi Aventis U.S. Llc1964-11-20Not applicableUs
Norpramintablet, sugar coated150 mg/1oralSanofi Aventis U.S. Llc1964-11-20Not applicableUs
Norpramintablet, sugar coated50 mg/1oralSanofi Aventis U.S. Llc1964-11-20Not applicableUs
Norpramintablet, sugar coated75 mg/1oralSanofi Aventis U.S. Llc1964-11-20Not applicableUs
Norpramin 100mg Tabtablet100 mgoralAventis Pharma Inc1995-12-312002-07-29Canada
Norpramin 10mg Tabtablet10 mgoralAventis Pharma Inc1995-12-312003-07-22Canada
Norpramin 25mg Tabtablet25 mgoralSanofi Aventis Canada Inc1995-12-312007-08-01Canada
Norpramin 50mg Tabtablet50 mgoralSanofi Aventis Canada Inc1995-12-312007-08-01Canada
Norpramin 75mg Tabtablet75 mgoralAventis Pharma Inc1996-12-312000-08-16Canada
Norpramin Tab 25mgtablet25 mgoralMerrell Pharms Inc., Division Of Merrell Dow (Can)1976-12-311996-09-09Canada
Norpramin Tab 50mgtablet50 mgoralMerrell Pharms Inc., Division Of Merrell Dow (Can)1976-12-311997-08-05Canada
Norpramin Tab 75mgtablet75 mgoralMerrell Pharms Inc., Division Of Merrell Dow (Can)1978-12-311997-08-05Canada
Novo-desipramine Fc - 50mg Tabtablet50 mgoralNovopharm Limited1996-11-27Not applicableCanada
Novo-desipramine Sc - Tab 10mgtablet10 mgoralNovopharm Limited1996-11-27Not applicableCanada
Novo-desipramine Sc - Tab 25mgtablet25 mgoralNovopharm Limited1996-11-27Not applicableCanada
Novo-desipramine Sc -tab 75mgtablet75 mgoralNovopharm Limited1996-11-27Not applicableCanada
Nu-desipramine - Tab 100mgtablet100 mgoralNu Pharm Inc1996-09-132012-09-04Canada
Nu-desipramine - Tab 10mgtablet10 mgoralNu Pharm Inc1996-12-312012-09-04Canada
Nu-desipramine - Tab 25mgtablet25 mgoralNu Pharm Inc1996-12-312012-09-04Canada
Nu-desipramine - Tab 50mgtablet50 mgoralNu Pharm Inc1996-12-312012-09-04Canada
Nu-desipramine - Tab 75mgtablet75 mgoralNu Pharm Inc1996-12-312012-09-04Canada
Penta-desipramine Tabletstablet10 mgoralPentapharm Ltd.Not applicableNot applicableCanada
Penta-desipramine Tabletstablet25 mgoralPentapharm Ltd.Not applicableNot applicableCanada
Penta-desipramine Tabletstablet50 mgoralPentapharm Ltd.Not applicableNot applicableCanada
Penta-desipramine Tabletstablet75 mgoralPentapharm Ltd.Not applicableNot applicableCanada
Pertofrane 25mgtablet25 mgoralNovartis Pharmaceuticals Canada Inc1964-12-311999-08-04Canada
Pertofrane Tab 50mgtablet50 mgoralGeigy Pharmaceuticals, Ciba Geigy Canada Ltd.1990-12-311996-11-08Canada
PHL-desipraminetablet10 mgoralPharmel Inc1998-02-172009-10-26Canada
PHL-desipraminetablet100 mgoralPharmel IncNot applicableNot applicableCanada
PHL-desipraminetablet25 mgoralPharmel Inc1998-02-172009-10-26Canada
PHL-desipraminetablet50 mgoralPharmel Inc1998-02-172009-10-26Canada
PHL-desipraminetablet75 mgoralPharmel Inc1998-02-172009-10-26Canada
PMS Desipramine Hydro Tab 10mgtablet10 mgoralPharmascience Inc1993-12-31Not applicableCanada
PMS Desipramine Hydro Tab 25mgtablet25 mgoralPharmascience Inc1993-12-31Not applicableCanada
PMS Desipramine Hydro Tab 50mgtablet50 mgoralPharmascience Inc1993-12-31Not applicableCanada
PMS Desipramine Hydro Tab 75mgtablet75 mgoralPharmascience Inc1993-12-31Not applicableCanada
PMS-desipramine - Tab 100mgtablet100 mgoralPharmascience Inc1995-12-31Not applicableCanada
Ratio-desipramine Tab 100mgtablet100 mgoralRatiopharm Inc Division Of Teva Canada Limited2002-07-262006-08-04Canada
Ratio-desipramine Tab 10mgtablet10 mgoralRatiopharm Inc Division Of Teva Canada Limited1994-12-312006-08-04Canada
Ratio-desipramine Tab 25mgtablet25 mgoralRatiopharm Inc Division Of Teva Canada Limited1992-12-312008-08-01Canada
Ratio-desipramine Tab 50mgtablet50 mgoralRatiopharm Inc Division Of Teva Canada Limited1992-12-312008-08-01Canada
Ratio-desipramine Tab 75mgtablet75 mgoralRatiopharm Inc Division Of Teva Canada Limited1992-12-312006-08-04Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Desipramine Hydrochloridetablet, film coated10 mg/1oralSandoz Inc2015-06-24Not applicableUs
Desipramine Hydrochloridetablet25 mg/1oralREMEDYREPACK INC.2011-10-12Not applicableUs
Desipramine Hydrochloridetablet, film coated10 mg/1oralKAISER FOUNDATION HOSPITALS2012-05-31Not applicableUs
Desipramine Hydrochloridetablet, film coated75 mg/1oralActavis Pharma, Inc.2006-05-08Not applicableUs
Desipramine Hydrochloridetablet, film coated25 mg/1oralAmneal Pharmaceuticals of New York, LLC2016-03-21Not applicableUs
Desipramine Hydrochloridetablet10 mg/1oralRebel Distributors Corp1996-02-09Not applicableUs
Desipramine Hydrochloridetablet, film coated25 mg/1oralAmerican Health Packaging2015-09-01Not applicableUs
Desipramine Hydrochloridetablet, film coated150 mg/1oralAmneal Pharmaceuticals of New York, LLC2016-03-21Not applicableUs
Desipramine Hydrochloridetablet, film coated75 mg/1oralSandoz Inc1988-06-20Not applicableUs
Desipramine Hydrochloridetablet10 mg/1oralREMEDYREPACK INC.2011-04-18Not applicableUs
Desipramine Hydrochloridetablet, film coated100 mg/1oralSTAT Rx USA LLC1988-06-20Not applicableUs
Desipramine Hydrochloridetablet, film coated25 mg/1oralbryant ranch prepack1988-05-24Not applicableUs
Desipramine Hydrochloridetablet, film coated10 mg/1oralSandoz Inc1988-05-24Not applicableUs
Desipramine Hydrochloridetablet, film coated100 mg/1oralActavis Pharma, Inc.2006-07-19Not applicableUs
Desipramine Hydrochloridetablet, film coated50 mg/1oralAmneal Pharmaceuticals of New York, LLC2016-03-21Not applicableUs
Desipramine Hydrochloridetablet, film coated10 mg/1oralCarilion Materials Management1988-05-24Not applicableUs
Desipramine Hydrochloridetablet, film coated10 mg/1oralActavis Pharma, Inc.2006-05-09Not applicableUs
Desipramine Hydrochloridetablet, film coated50 mg/1oralREMEDYREPACK INC.2011-04-21Not applicableUs
Desipramine Hydrochloridetablet, film coated100 mg/1oralSandoz Inc1988-06-20Not applicableUs
Desipramine Hydrochloridetablet, film coated10 mg/1oralSTAT Rx USA LLC1988-05-24Not applicableUs
Desipramine Hydrochloridetablet, film coated100 mg/1oralbryant ranch prepack1988-06-20Not applicableUs
Desipramine Hydrochloridetablet, film coated25 mg/1oralSandoz Inc1988-05-24Not applicableUs
Desipramine Hydrochloridetablet, film coated150 mg/1oralActavis Pharma, Inc.2006-05-09Not applicableUs
Desipramine Hydrochloridetablet, film coated75 mg/1oralAmneal Pharmaceuticals of New York, LLC2016-03-21Not applicableUs
Desipramine Hydrochloridetablet, film coated25 mg/1oralPreferred Pharmaceuticals, Inc2012-04-05Not applicableUs
Desipramine Hydrochloridetablet, film coated25 mg/1oralActavis Pharma, Inc.2006-05-01Not applicableUs
Desipramine Hydrochloridetablet50 mg/1oralREMEDYREPACK INC.2011-09-19Not applicableUs
Desipramine Hydrochloridetablet, film coated150 mg/1oralSandoz Inc1988-06-20Not applicableUs
Desipramine Hydrochloridetablet, film coated25 mg/1oralRebel Distributors Corp1988-05-24Not applicableUs
Desipramine Hydrochloridetablet, film coated50 mg/1oralbryant ranch prepack2006-06-04Not applicableUs
Desipramine Hydrochloridetablet, film coated50 mg/1oralSandoz Inc1988-05-24Not applicableUs
Desipramine Hydrochloridetablet50 mg/1oralREMEDYREPACK INC.2011-04-04Not applicableUs
Desipramine Hydrochloridetablet, film coated100 mg/1oralAmneal Pharmaceuticals of New York, LLC2016-03-21Not applicableUs
Desipramine Hydrochloridetablet, film coated10 mg/1oralAmneal Pharmaceuticals of New York, LLC2016-03-21Not applicableUs
Desipramine Hydrochloridetablet, film coated50 mg/1oralActavis Pharma, Inc.2006-06-04Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
PertofranCiba
PertofraneUSV
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Desipramine Hydrochloride
Thumb
  • InChI Key: XAEWZDYWZHIUCT-UHFFFAOYSA-N
  • Monoisotopic Mass: 302.154976453
  • Average Mass: 302.842
DBSALT000042
Categories
UNIITG537D343B
CAS number50-47-5
WeightAverage: 266.3807
Monoisotopic: 266.178298714
Chemical FormulaC18H22N2
InChI KeyInChIKey=HCYAFALTSJYZDH-UHFFFAOYSA-N
InChI
InChI=1S/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3
IUPAC Name
(3-{2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}propyl)(methyl)amine
SMILES
CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzazepines
Sub ClassDibenzazepines
Direct ParentDibenzazepines
Alternative Parents
Substituents
  • Dibenzazepine
  • Alkyldiarylamine
  • Azepine
  • Benzenoid
  • Tertiary amine
  • Azacycle
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor relief of symptoms in various depressive syndromes, especially endogenous depression. It has also been used to manage chronic peripheral neuropathic pain, as a second line agent for the management of anxiety disorders (e.g. panic disorder, generalized anxiety disorder), and as a second or third line agent in the ADHD management.
PharmacodynamicsDesipramine, a secondary amine tricyclic antidepressant, is structurally related to both the skeletal muscle relaxant cyclobenzaprine and the thioxanthene antipsychotics such as thiothixene. It is the active metabolite of imipramine, a tertiary amine TCA. The acute effects of desipramine include inhibition of noradrenaline re-uptake at noradrenergic nerve endings and inhibition of serotonin (5-hydroxy tryptamine, 5HT) re-uptake at the serotoninergic nerve endings in the central nervous system. Desipramine exhibits greater noradrenergic re-uptake inhibition compared to the tertiary amine TCA imipramine. In addition to inhibiting neurotransmitter re-uptake, desipramine down-regulates beta-adrenergic receptors in the cerebral cortex and sensitizes serotonergic receptors with chronic use. The overall effect is increased serotonergic transmission. Antidepressant effects are typically observed 2 - 4 weeks following the onset of therapy though some patients may require up to 8 weeks of therapy prior to symptom improvement. Patients experiencing more severe depressive episodes may respond quicker than those with mild depressive symptoms.
Mechanism of actionDesipramine is a tricyclic antidepressant (TCA) that selectively blocks reuptake of norepinephrine (noradrenaline) from the neuronal synapse. It also inhibits serotonin reuptake, but to a lesser extent compared to tertiary amine TCAs such as imipramine. Inhibition of neurotransmitter reuptake increases stimulation of the post-synaptic neuron. Chronic use of desipramine also leads to down-regulation of beta-adrenergic receptors in the cerebral cortex and sensitization of serotonergic receptors. An overall increase in serotonergic transmission likely confers desipramine its antidepressant effects. Desipramine also possesses minor anticholinergic activity, through its affinity for muscarinic receptors. TCAs are believed to act by restoring normal levels of neurotransmitters via synaptic reuptake inhibition and by increasing serotonergic neurotransmission via serotonergic receptor sensitization in the central nervous system.
Related Articles
AbsorptionDesipramine hydrochloride is rapidly and almost completely absorbed from the gastrointestinal tract. It undergoes extensive first-pass metabolism. Peak plasma concentrations are attained 4 - 6 hours following oral administration.
Volume of distributionNot Available
Protein binding73-92% bound to plasma proteins
Metabolism

Desipramine is extensively metabolized in the liver by CYP2D6 (major) and CYP1A2 (minor) to 2-hydroxydesipramine, an active metabolite. 2-hydroxydesipramine is thought to retain some amine reuptake inhibition and may possess cardiac depressant activity. The 2-hydroxylation metabolic pathway of desipramine is under genetic control.

SubstrateEnzymesProduct
Desipramine
2-hydroxydesipramineDetails
2-hydroxydesipramine
Not Available
2-hydroxy-desipramine glucuronideDetails
Route of eliminationDesipramine is metabolized in the liver, and approximately 70% is excreted in the urine.
Half life7-60+ hours; 70% eliminated renally
ClearanceNot Available
ToxicityMale mice: LD50 = 290 mg/kg, female rats: LD50 = 320 mg/kg. Antagonism of the histamine H1 and α1 receptors can lead to sedation and hypotension. Antimuscarinic activity confers anticholinergic side effects such as blurred vision, dry mouth, constipation and urine retention may occur. Cardiotoxicity may occur with high doses of desipramine. Cardiovascular side effects in postural hypotension, tachycardia, hypertension, ECG changes and congestive heart failure. Psychotoxic effects include impaired memory and delirium. Induction of hypomanic or manic episodes may occur in patients with a history of bipolar disorder. Withdrawal symptoms include GI disturbances (e.g. nausea, vomiting, abdominal pain, diarrhea), anxiety, insomnia, nervousness, headache and malaise.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Desipramine Action PathwayDrug actionSMP00423
Imipramine Action PathwayDrug actionSMP00422
Imipramine Metabolism PathwayDrug metabolismSMP00625
Desipramine Metabolism PathwayDrug metabolismSMP00626
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Cytochrome P450 2D6
Gene symbol: CYP2D6
UniProt: P10635
rs3892097 CYP2D6*4A AllelePoor drug metabolizer, lower dose requirements, higher risk for adverse side effects18070221
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9958
Blood Brain Barrier+0.9854
Caco-2 permeable+0.8868
P-glycoprotein substrateSubstrate0.7945
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IINon-inhibitor0.6353
Renal organic cation transporterInhibitor0.7955
CYP450 2C9 substrateNon-substrate0.7684
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.5117
CYP450 1A2 substrateInhibitor0.9029
CYP450 2C9 inhibitorNon-inhibitor0.9125
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9241
CYP450 3A4 inhibitorInhibitor0.744
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8478
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9476
BiodegradationNot ready biodegradable0.9686
Rat acute toxicity2.8197 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8569
hERG inhibition (predictor II)Inhibitor0.8604
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral10 mg/1
Tabletoral25 mg/1
Tabletoral50 mg/1
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral100 mg/1
Tablet, film coatedoral150 mg/1
Tablet, film coatedoral25 mg/1
Tablet, film coatedoral50 mg/1
Tablet, film coatedoral75 mg/1
Tablet, sugar coatedoral10 mg/1
Tablet, sugar coatedoral100 mg/1
Tablet, sugar coatedoral150 mg/1
Tablet, sugar coatedoral25 mg/1
Tablet, sugar coatedoral50 mg/1
Tablet, sugar coatedoral75 mg/1
Tabletoral10 mg
Tabletoral25 mg
Tabletoral50 mg
Tabletoral75 mg
Tabletoral100 mg
Prices
Unit descriptionCostUnit
Desipramine hcl powder14.4USD g
Norpramin 150 mg tablet6.08USD tablet
Desipramine HCl 150 mg tablet4.67USD tablet
Norpramin 100 mg tablet4.2USD tablet
Norpramin 75 mg tablet3.19USD tablet
Desipramine HCl 100 mg tablet2.81USD tablet
Desipramine HCl 75 mg tablet2.63USD tablet
Norpramin 50 mg tablet2.51USD tablet
Desipramine 150 mg tablet2.18USD tablet
Desipramine HCl 50 mg tablet1.64USD tablet
Desipramine 100 mg tablet1.5USD tablet
Norpramin 25 mg tablet1.33USD tablet
Desipramine 75 mg tablet1.15USD tablet
Norpramin 10 mg tablet1.11USD tablet
Apo-Desipramine 75 mg Tablet0.93USD tablet
Desipramine 50 mg tablet0.92USD tablet
Desipramine HCl 10 mg tablet0.87USD tablet
Desipramine HCl 25 mg tablet0.83USD tablet
Apo-Desipramine 50 mg Tablet0.7USD tablet
Desipramine 25 mg tablet0.49USD tablet
Desipramine 10 mg tablet0.4USD tablet
Apo-Desipramine 10 mg Tablet0.4USD tablet
Apo-Desipramine 25 mg Tablet0.4USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point214-218 °CNot Available
water solubility58.6 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.90HANSCH,C ET AL. (1995)
logS-3.66ADME Research, USCD
Caco2 permeability-4.67ADME Research, USCD
pKa10.4SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0396 mg/mLALOGPS
logP4.02ALOGPS
logP3.9ChemAxon
logS-3.8ALOGPS
pKa (Strongest Basic)10.02ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area15.27 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity85.31 m3·mol-1ChemAxon
Polarizability31.74 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (11 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0006-4970000000-810535cb33c37107abc5View in MoNA
References
Synthesis Reference

Biel, J.H.and Judd, C.I.; US. Patent 3,454,554; July 8,1969; assigned to Colgate Palmolive Co.

General ReferencesNot Available
External Links
ATC CodesN06AA01
AHFS Codes
  • 28:16.04.28
PDB EntriesNot Available
FDA labelDownload (152 KB)
MSDSDownload (73.6 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe serum concentration of Desipramine can be increased when it is combined with 1,10-Phenanthroline.
3,4-DichloroisocoumarinThe serum concentration of Desipramine can be increased when it is combined with 3,4-Dichloroisocoumarin.
3,4-MethylenedioxyamphetamineDesipramine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineDesipramine may increase the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Desipramine can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.
4-MethoxyamphetamineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Desipramine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Desipramine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Desipramine.
AbirateroneThe serum concentration of Desipramine can be increased when it is combined with Abiraterone.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Desipramine.
AcenocoumarolDesipramine may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Desipramine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Desipramine is combined with Aceprometazine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Desipramine.
AcetophenazineThe risk or severity of adverse effects can be increased when Desipramine is combined with Acetophenazine.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Desipramine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Desipramine.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Desipramine.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Desipramine.
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Desipramine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Desipramine.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Desipramine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Desipramine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Desipramine.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Desipramine.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Desipramine.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Desipramine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Desipramine.
AlogliptinThe serum concentration of Desipramine can be increased when it is combined with Alogliptin.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Desipramine.
Alpha-1-proteinase inhibitorThe serum concentration of Desipramine can be increased when it is combined with Alpha-1-proteinase inhibitor.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Desipramine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Desipramine.
AlprenololThe metabolism of Alprenolol can be decreased when combined with Desipramine.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Desipramine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Desipramine.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Desipramine.
AmiodaroneThe metabolism of Desipramine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Desipramine is combined with Amisulpride.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Desipramine.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Desipramine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Desipramine.
AmoxapineThe risk or severity of adverse effects can be increased when Desipramine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Desipramine is combined with Amperozide.
AmphetamineDesipramine may increase the stimulatory activities of Amphetamine.
AmprenavirThe serum concentration of Desipramine can be increased when it is combined with Amprenavir.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Desipramine.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Desipramine.
AnagrelideDesipramine may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Desipramine.
Antithrombin III humanThe serum concentration of Desipramine can be increased when it is combined with Antithrombin III human.
ApixabanThe serum concentration of Desipramine can be increased when it is combined with Apixaban.
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Desipramine.
ApraclonidineThe therapeutic efficacy of Apraclonidine can be decreased when used in combination with Desipramine.
AprindineThe metabolism of Aprindine can be decreased when combined with Desipramine.
AprotininThe serum concentration of Desipramine can be increased when it is combined with Aprotinin.
ArbutamineThe risk or severity of adverse effects can be increased when Desipramine is combined with Arbutamine.
ArformoterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Arformoterol.
ArgatrobanThe serum concentration of Desipramine can be increased when it is combined with Argatroban.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Desipramine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Desipramine.
ArmodafinilThe metabolism of Desipramine can be decreased when combined with Armodafinil.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Desipramine.
ArtemetherThe metabolism of Artemether can be decreased when combined with Desipramine.
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Desipramine resulting in a loss in efficacy.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Desipramine.
AsenapineThe risk or severity of adverse effects can be increased when Desipramine is combined with Asenapine.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Desipramine.
AsunaprevirThe serum concentration of Desipramine can be increased when it is combined with Asunaprevir.
AtazanavirThe serum concentration of Desipramine can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Desipramine.
AtomoxetineThe metabolism of Desipramine can be decreased when combined with Atomoxetine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Desipramine.
AzaperoneThe risk or severity of adverse effects can be increased when Desipramine is combined with Azaperone.
AzelastineDesipramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Desipramine.
AzithromycinDesipramine may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe metabolism of Desipramine can be decreased when combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Desipramine.
BambuterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Bambuterol.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Desipramine.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Desipramine.
BatimastatThe serum concentration of Desipramine can be increased when it is combined with Batimastat.
BedaquilineDesipramine may increase the QTc-prolonging activities of Bedaquiline.
BenazeprilThe serum concentration of Desipramine can be increased when it is combined with Benazepril.
BenmoxinBenmoxin may increase the serotonergic activities of Desipramine.
BenzamidineThe serum concentration of Desipramine can be increased when it is combined with Benzamidine.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Desipramine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Desipramine.
BenzphetamineDesipramine may increase the stimulatory activities of Benzphetamine.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Desipramine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Desipramine.
BepridilThe metabolism of Bepridil can be decreased when combined with Desipramine.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Desipramine.
BetaxololThe metabolism of Desipramine can be decreased when combined with Betaxolol.
BethanidineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Desipramine.
BifeprunoxThe risk or severity of adverse effects can be increased when Desipramine is combined with Bifeprunox.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Desipramine.
BivalirudinThe serum concentration of Desipramine can be increased when it is combined with Bivalirudin.
BoceprevirThe serum concentration of Desipramine can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Desipramine can be decreased when combined with Bortezomib.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Desipramine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Desipramine.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Desipramine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Desipramine.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
BrimonidineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Desipramine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Desipramine.
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Desipramine.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Desipramine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Desipramine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Desipramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Desipramine.
BufuralolThe metabolism of Bufuralol can be decreased when combined with Desipramine.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Desipramine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Desipramine.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Desipramine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Desipramine.
BupropionThe serum concentration of Bupropion can be increased when it is combined with Desipramine.
BupropionThe metabolism of Desipramine can be decreased when combined with Bupropion.
BuspironeThe metabolism of Buspirone can be decreased when combined with Desipramine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Desipramine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Desipramine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Desipramine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Desipramine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Desipramine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Desipramine.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Desipramine.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Desipramine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Desipramine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Desipramine.
CaffeineThe metabolism of Desipramine can be decreased when combined with Caffeine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Desipramine.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Desipramine.
CandoxatrilThe serum concentration of Desipramine can be increased when it is combined with Candoxatril.
CaptoprilThe serum concentration of Desipramine can be increased when it is combined with Captopril.
CaptoprilThe metabolism of Captopril can be decreased when combined with Desipramine.
CarbamazepineThe metabolism of Desipramine can be increased when combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Desipramine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Desipramine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Desipramine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Desipramine.
CariprazineThe risk or severity of adverse effects can be increased when Desipramine is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Desipramine.
CaroxazoneCaroxazone may increase the serotonergic activities of Desipramine.
CarteololThe metabolism of Carteolol can be decreased when combined with Desipramine.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Desipramine.
CelecoxibThe metabolism of Desipramine can be decreased when combined with Celecoxib.
CeliprololThe risk or severity of adverse effects can be increased when Desipramine is combined with Celiprolol.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Desipramine.
CeritinibDesipramine may increase the QTc-prolonging activities of Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Desipramine.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Desipramine.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Desipramine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Desipramine.
ChloramphenicolThe metabolism of Desipramine can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Desipramine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Desipramine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Desipramine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Desipramine.
ChloroquineDesipramine may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe metabolism of Desipramine can be decreased when combined with Chloroquine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Desipramine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Desipramine.
ChlorphentermineDesipramine may increase the stimulatory activities of Chlorphentermine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Desipramine is combined with Chlorpromazine.
ChlorpromazineThe metabolism of Desipramine can be decreased when combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Desipramine is combined with Chlorprothixene.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Desipramine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Desipramine.
CholecalciferolThe metabolism of Desipramine can be decreased when combined with Cholecalciferol.
ChymostatinThe serum concentration of Desipramine can be increased when it is combined with Chymostatin.
CilastatinThe serum concentration of Desipramine can be increased when it is combined with Cilastatin.
CilazaprilThe serum concentration of Desipramine can be increased when it is combined with Cilazapril.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Desipramine.
CimetidineThe metabolism of Desipramine can be decreased when combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Desipramine.
CinacalcetThe serum concentration of Desipramine can be increased when it is combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Desipramine.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Desipramine.
CiprofloxacinDesipramine may increase the QTc-prolonging activities of Ciprofloxacin.
CirazolineDesipramine may increase the vasopressor activities of Cirazoline.
CisaprideThe metabolism of Cisapride can be decreased when combined with Desipramine.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Desipramine.
CitalopramThe risk or severity of adverse effects can be increased when Desipramine is combined with Citalopram.
CitalopramThe metabolism of Desipramine can be decreased when combined with Citalopram.
ClarithromycinDesipramine may increase the QTc-prolonging activities of Clarithromycin.
ClemastineThe metabolism of Desipramine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Desipramine is combined with Clemastine.
ClenbuterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Clenbuterol.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Desipramine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Desipramine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Desipramine.
ClobazamThe metabolism of Desipramine can be decreased when combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Desipramine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Desipramine.
ClomipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Clomipramine.
ClomipramineThe metabolism of Desipramine can be decreased when combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Desipramine.
ClonidineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Desipramine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Desipramine.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Desipramine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Desipramine.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Desipramine.
ClotrimazoleThe metabolism of Desipramine can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Desipramine is combined with Clozapine.
ClozapineThe metabolism of Desipramine can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Desipramine can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Desipramine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Desipramine.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Desipramine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Desipramine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Desipramine.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Desipramine.
CrizotinibDesipramine may increase the QTc-prolonging activities of Crizotinib.
CyamemazineThe risk or severity of adverse effects can be increased when Desipramine is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Desipramine is combined with Cyclizine.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Desipramine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desipramine.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Desipramine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Desipramine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Desipramine.
Cyproterone acetateThe serum concentration of Desipramine can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Desipramine can be increased when it is combined with Dabigatran etexilate.
DabrafenibThe serum concentration of Desipramine can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Desipramine.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Desipramine.
DantroleneThe risk or severity of adverse effects can be increased when Desipramine is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Desipramine.
DapiprazoleThe risk or severity of adverse effects can be increased when Desipramine is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Desipramine.
DarifenacinThe metabolism of Desipramine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Desipramine can be increased when it is combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Desipramine.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Desipramine.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Desipramine.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Desipramine.
DeferasiroxThe serum concentration of Desipramine can be increased when it is combined with Deferasirox.
DelavirdineThe metabolism of Desipramine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Desipramine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Desipramine.
DesmopressinThe risk or severity of adverse effects can be increased when Desipramine is combined with Desmopressin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desipramine is combined with Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Desipramine.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Desipramine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Desipramine.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Desipramine.
DexmedetomidineThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Desipramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Desipramine.
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Desipramine.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Desipramine.
DextroamphetamineDesipramine may increase the stimulatory activities of Dextroamphetamine.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Desipramine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Desipramine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Desipramine.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Desipramine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Desipramine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Desipramine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Desipramine.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Desipramine.
DicoumarolDesipramine may increase the anticoagulant activities of Dicoumarol.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Desipramine.
DifenoxinThe risk or severity of adverse effects can be increased when Desipramine is combined with Difenoxin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Desipramine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Desipramine.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Desipramine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Desipramine.
DihydroergotamineThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Desipramine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Desipramine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Desipramine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Desipramine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Desipramine.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Desipramine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Desipramine.
DiphenhydramineThe metabolism of Desipramine can be decreased when combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Desipramine.
DipivefrinThe therapeutic efficacy of Dipivefrin can be decreased when used in combination with Desipramine.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Desipramine.
DisopyramideDesipramine may increase the QTc-prolonging activities of Disopyramide.
DobutamineThe risk or severity of adverse effects can be increased when Desipramine is combined with Dobutamine.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Desipramine.
DofetilideDesipramine may increase the QTc-prolonging activities of Dofetilide.
DolasetronDesipramine may increase the QTc-prolonging activities of Dolasetron.
DolasetronDolasetron may increase the serotonergic activities of Desipramine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Desipramine.
DonepezilThe metabolism of Donepezil can be decreased when combined with Desipramine.
DopamineThe metabolism of Dopamine can be decreased when combined with Desipramine.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Desipramine.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Desipramine.
DoxepinThe metabolism of Doxepin can be decreased when combined with Desipramine.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Desipramine.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Desipramine.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
DoxylamineThe risk or severity of adverse effects can be increased when Desipramine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Desipramine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Desipramine.
DroperidolThe risk or severity of adverse effects can be increased when Desipramine is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Desipramine.
DroxidopaThe therapeutic efficacy of Droxidopa can be decreased when used in combination with Desipramine.
DuloxetineThe metabolism of Desipramine can be decreased when combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Desipramine.
EcabetThe serum concentration of Desipramine can be increased when it is combined with Ecabet.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Desipramine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Desipramine.
EdoxabanThe serum concentration of Desipramine can be increased when it is combined with Edoxaban.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Desipramine.
ElafinThe serum concentration of Desipramine can be increased when it is combined with Elafin.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Desipramine.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Desipramine.
EliglustatThe metabolism of Eliglustat can be decreased when combined with Desipramine.
EnalaprilThe serum concentration of Desipramine can be increased when it is combined with Enalapril.
EnalaprilatThe serum concentration of Desipramine can be increased when it is combined with Enalaprilat.
EnalkirenThe serum concentration of Desipramine can be increased when it is combined with Enalkiren.
EncainideThe metabolism of Encainide can be decreased when combined with Desipramine.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Desipramine.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Desipramine.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Desipramine.
EphedraThe therapeutic efficacy of Ephedra can be decreased when used in combination with Desipramine.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Desipramine.
EpinephrineThe therapeutic efficacy of Epinephrine can be decreased when used in combination with Desipramine.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Desipramine.
ErgonovineThe risk or severity of adverse effects can be increased when Desipramine is combined with Ergonovine.
ErgotamineDesipramine may increase the vasopressor activities of Ergotamine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Desipramine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Desipramine.
ErythromycinDesipramine may increase the QTc-prolonging activities of Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Desipramine is combined with Escitalopram.
Eslicarbazepine acetateThe metabolism of Desipramine can be decreased when combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Desipramine.
EsomeprazoleThe metabolism of Desipramine can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Desipramine.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Desipramine.
EstriolThe serum concentration of Estriol can be increased when it is combined with Desipramine.
EstroneThe serum concentration of Estrone can be increased when it is combined with Desipramine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Desipramine.
EthanolDesipramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Desipramine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Desipramine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Desipramine.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Desipramine.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Desipramine.
Ethyl biscoumacetateDesipramine may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Desipramine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Desipramine.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Desipramine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Desipramine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Desipramine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Desipramine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Desipramine.
EtomidateThe therapeutic efficacy of Etomidate can be decreased when used in combination with Desipramine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Desipramine.
EtoperidoneThe risk or severity of adverse effects can be increased when Desipramine is combined with Etoperidone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Desipramine.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Desipramine.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Desipramine.
EtravirineThe metabolism of Desipramine can be decreased when combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Desipramine.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Desipramine.
EzogabineThe risk or severity of adverse effects can be increased when Desipramine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Desipramine.
FencamfamineThe risk or severity of adverse effects can be increased when Desipramine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Fenfluramine.
FenoterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Fenoterol.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Desipramine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Desipramine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Desipramine.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Desipramine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Desipramine.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Desipramine.
FlecainideDesipramine may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe risk or severity of adverse effects can be increased when Desipramine is combined with Flibanserin.
FluconazoleThe metabolism of Desipramine can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Desipramine.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Desipramine.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Desipramine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Desipramine.
FluoxetineThe risk or severity of adverse effects can be increased when Desipramine is combined with Fluoxetine.
FluoxetineThe metabolism of Desipramine can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Desipramine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Desipramine is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Desipramine.
FluspirileneThe risk or severity of adverse effects can be increased when Desipramine is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Desipramine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Desipramine.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Desipramine.
FluvoxamineThe risk or severity of adverse effects can be increased when Desipramine is combined with Fluvoxamine.
FluvoxamineThe metabolism of Desipramine can be decreased when combined with Fluvoxamine.
FormoterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Formoterol.
FosamprenavirThe serum concentration of Desipramine can be increased when it is combined with Fosamprenavir.
FosinoprilThe serum concentration of Desipramine can be increased when it is combined with Fosinopril.
FosphenytoinThe risk or severity of adverse effects can be increased when Desipramine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Desipramine.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Desipramine.
FurazolidoneFurazolidone may increase the serotonergic activities of Desipramine.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Desipramine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Desipramine is combined with gabapentin enacarbil.
Gadobenic acidDesipramine may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineThe metabolism of Galantamine can be decreased when combined with Desipramine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Desipramine.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Desipramine.
GeldanamycinThe serum concentration of Desipramine can be increased when it is combined with Geldanamycin.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Desipramine.
GemfibrozilThe metabolism of Desipramine can be decreased when combined with Gemfibrozil.
GemifloxacinDesipramine may increase the QTc-prolonging activities of Gemifloxacin.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Desipramine.
GM6001The serum concentration of Desipramine can be increased when it is combined with GM6001.
GoserelinDesipramine may increase the QTc-prolonging activities of Goserelin.
GranisetronDesipramine may increase the QTc-prolonging activities of Granisetron.
GranisetronGranisetron may increase the serotonergic activities of Desipramine.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Desipramine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Desipramine.
GuanabenzThe therapeutic efficacy of Guanabenz can be decreased when used in combination with Desipramine.
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Desipramine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Desipramine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Desipramine.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Desipramine.
HaloperidolThe risk or severity of adverse effects can be increased when Desipramine is combined with Haloperidol.
HaloperidolThe metabolism of Desipramine can be decreased when combined with Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Desipramine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Desipramine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Desipramine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Desipramine.
HirulogThe serum concentration of Desipramine can be increased when it is combined with Hirulog.
HydracarbazineHydracarbazine may increase the serotonergic activities of Desipramine.
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Desipramine.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Desipramine.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Desipramine.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Desipramine.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Desipramine.
Hydroxyamphetamine hydrobromideDesipramine may increase the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
HydroxyzineThe risk or severity of adverse effects can be increased when Desipramine is combined with Hydroxyzine.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Desipramine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Desipramine.
IbutilideDesipramine may increase the QTc-prolonging activities of Ibutilide.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Desipramine.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Desipramine.
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Desipramine.
IloperidoneThe risk or severity of adverse effects can be increased when Desipramine is combined with Iloperidone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Desipramine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Desipramine.
ImipramineThe metabolism of Desipramine can be decreased when combined with Imipramine.
IndacaterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Indacaterol.
IndalpineThe risk or severity of adverse effects can be increased when Desipramine is combined with Indalpine.
IndinavirThe serum concentration of Desipramine can be increased when it is combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Desipramine.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Desipramine.
IproclozideIproclozide may increase the serotonergic activities of Desipramine.
IproniazidIproniazid may increase the serotonergic activities of Desipramine.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Desipramine.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Desipramine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Desipramine is combined with Isocarboxazid.
IsoetarineThe risk or severity of adverse effects can be increased when Desipramine is combined with Isoetarine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Desipramine.
IsoflurophateThe serum concentration of Desipramine can be increased when it is combined with Isoflurophate.
IsoniazidThe metabolism of Desipramine can be decreased when combined with Isoniazid.
IsoprenalineThe risk or severity of adverse effects can be increased when Desipramine is combined with Isoprenaline.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Desipramine.
IxazomibThe serum concentration of Desipramine can be increased when it is combined with Ixazomib.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Desipramine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Desipramine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Desipramine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Desipramine.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Desipramine.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Desipramine.
KetoconazoleThe metabolism of Desipramine can be decreased when combined with Ketoconazole.
LabetalolThe metabolism of Labetalol can be decreased when combined with Desipramine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Desipramine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Desipramine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Desipramine.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Desipramine.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Desipramine.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Desipramine.
LenvatinibDesipramine may increase the QTc-prolonging activities of Lenvatinib.
LepirudinThe serum concentration of Desipramine can be increased when it is combined with Lepirudin.
LeuprolideDesipramine may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Desipramine.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Desipramine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Desipramine.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Desipramine.
LevocetirizineThe risk or severity of adverse effects can be increased when Desipramine is combined with Levocetirizine.
LevodopaThe metabolism of Levodopa can be decreased when combined with Desipramine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Desipramine.
LevofloxacinDesipramine may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Desipramine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Desipramine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Desipramine.
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Desipramine.
LidocaineThe metabolism of Desipramine can be decreased when combined with Lidocaine.
LinagliptinThe serum concentration of Desipramine can be increased when it is combined with Linagliptin.
LinezolidLinezolid may increase the serotonergic activities of Desipramine.
LinezolidThe risk or severity of adverse effects can be increased when Desipramine is combined with Linezolid.
LiothyronineLiothyronine may increase the arrhythmogenic activities of Desipramine.
LiotrixLiotrix may increase the arrhythmogenic activities of Desipramine.
LisdexamfetamineDesipramine may increase the stimulatory activities of Lisdexamfetamine.
LisinoprilThe serum concentration of Desipramine can be increased when it is combined with Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Desipramine.
LithiumThe risk or severity of adverse effects can be increased when Desipramine is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Desipramine.
LofexidineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Desipramine.
LomustineThe metabolism of Lomustine can be decreased when combined with Desipramine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Desipramine.
LopinavirThe serum concentration of Desipramine can be increased when it is combined with Lopinavir.
LopinavirDesipramine may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Desipramine.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Desipramine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Desipramine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Desipramine.
LosartanThe serum concentration of Losartan can be increased when it is combined with Desipramine.
LoxapineThe risk or severity of adverse effects can be increased when Desipramine is combined with Loxapine.
Lu AA21004The risk or severity of adverse effects can be increased when Desipramine is combined with Lu AA21004.
LuliconazoleThe serum concentration of Desipramine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Desipramine can be decreased when it is combined with Lumacaftor.
LumefantrineDesipramine may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Desipramine can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Desipramine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Desipramine is combined with Magnesium Sulfate.
MalathionThe metabolism of Malathion can be decreased when combined with Desipramine.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Desipramine.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Desipramine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Desipramine.
MebanazineMebanazine may increase the serotonergic activities of Desipramine.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Desipramine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Desipramine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Desipramine.
MelperoneThe risk or severity of adverse effects can be increased when Desipramine is combined with Melperone.
MephentermineDesipramine may increase the stimulatory activities of Mephentermine.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Desipramine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Desipramine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Desipramine.
MequitazineThe metabolism of Mequitazine can be decreased when combined with Desipramine.
MesoridazineThe risk or severity of adverse effects can be increased when Desipramine is combined with Mesoridazine.
MetaraminolDesipramine may increase the vasopressor activities of Metaraminol.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Desipramine.
MethadoneDesipramine may increase the QTc-prolonging activities of Methadone.
MethadoneThe metabolism of Desipramine can be decreased when combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Desipramine.
MethamphetamineDesipramine may increase the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Desipramine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Desipramine.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Desipramine.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Desipramine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Desipramine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Desipramine is combined with Methotrimeprazine.
MethoxamineDesipramine may increase the vasopressor activities of Methoxamine.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Desipramine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Desipramine.
MethsuximideThe risk or severity of adverse effects can be increased when Desipramine is combined with Methsuximide.
Methylene blueDesipramine may increase the serotonergic activities of Methylene blue.
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Desipramine.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Desipramine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Desipramine.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Desipramine.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Desipramine.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Desipramine.
MetoclopramideThe risk or severity of adverse effects can be increased when Desipramine is combined with Metoclopramide.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Desipramine.
MetoprololThe metabolism of Desipramine can be decreased when combined with Metoprolol.
MetyrosineDesipramine may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Desipramine.
MexiletineThe metabolism of Desipramine can be decreased when combined with Mexiletine.
MianserinThe metabolism of Mianserin can be decreased when combined with Desipramine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Desipramine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Desipramine.
MidodrineDesipramine may increase the vasopressor activities of Midodrine.
MifepristoneMifepristone may increase the QTc-prolonging activities of Desipramine.
MilnacipranThe risk or severity of adverse effects can be increased when Desipramine is combined with Milnacipran.
MinaprineMinaprine may increase the serotonergic activities of Desipramine.
MinaprineThe metabolism of Minaprine can be decreased when combined with Desipramine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
MirabegronThe serum concentration of Desipramine can be increased when it is combined with Mirabegron.
MirtazapineDesipramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Desipramine.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Desipramine.
MoclobemideMoclobemide may increase the serotonergic activities of Desipramine.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Desipramine.
ModafinilThe metabolism of Desipramine can be decreased when combined with Modafinil.
MoexiprilThe serum concentration of Desipramine can be increased when it is combined with Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Desipramine is combined with Molindone.
MorphineThe serum concentration of Morphine can be increased when it is combined with Desipramine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Desipramine.
MoxifloxacinDesipramine may increase the QTc-prolonging activities of Moxifloxacin.
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Desipramine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Desipramine.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Desipramine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
NabiloneThe risk or severity of adverse effects can be increased when Desipramine is combined with Nabilone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Desipramine.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Desipramine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Desipramine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Desipramine.
NaphazolineThe therapeutic efficacy of Naphazoline can be decreased when used in combination with Desipramine.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Desipramine.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Desipramine.
NCX 4016The serum concentration of Desipramine can be increased when it is combined with NCX 4016.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Desipramine.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Desipramine.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Desipramine.
NelfinavirThe serum concentration of Desipramine can be increased when it is combined with Nelfinavir.
NetupitantThe metabolism of Netupitant can be decreased when combined with Desipramine.
NevirapineThe metabolism of Desipramine can be decreased when combined with Nevirapine.
NialamideNialamide may increase the serotonergic activities of Desipramine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Desipramine.
NicardipineThe metabolism of Desipramine can be decreased when combined with Nicardipine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Desipramine.
NicorandilDesipramine may increase the hypotensive activities of Nicorandil.
NicotineThe metabolism of Nicotine can be decreased when combined with Desipramine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Desipramine.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Desipramine.
NilotinibThe metabolism of Desipramine can be decreased when combined with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Desipramine.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Desipramine.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Desipramine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Desipramine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Desipramine.
NorepinephrineThe therapeutic efficacy of Norepinephrine can be decreased when used in combination with Desipramine.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Desipramine.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Desipramine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Desipramine.
OctamoxinOctamoxin may increase the serotonergic activities of Desipramine.
OfloxacinDesipramine may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe risk or severity of adverse effects can be increased when Desipramine is combined with Olanzapine.
OlodaterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Olodaterol.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desipramine.
OmapatrilatThe serum concentration of Desipramine can be increased when it is combined with Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Desipramine.
OmeprazoleThe metabolism of Desipramine can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Desipramine is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Desipramine.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Desipramine.
OrciprenalineThe risk or severity of adverse effects can be increased when Desipramine is combined with Orciprenaline.
OrphenadrineDesipramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Desipramine.
OsanetantThe risk or severity of adverse effects can be increased when Desipramine is combined with Osanetant.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Desipramine.
OsimertinibThe serum concentration of Desipramine can be decreased when it is combined with Osimertinib.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Desipramine.
OtamixabanThe serum concentration of Desipramine can be increased when it is combined with Otamixaban.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Desipramine.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Desipramine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Desipramine.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Desipramine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Desipramine.
OxymetazolineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Desipramine.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Desipramine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Desipramine.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Desipramine.
PaliperidoneThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Desipramine.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Desipramine.
PalonosetronPalonosetron may increase the serotonergic activities of Desipramine.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Desipramine.
PanobinostatDesipramine may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Desipramine can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Desipramine can be decreased when combined with Pantoprazole.
ParaldehydeDesipramine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Desipramine.
PargylinePargyline may increase the serotonergic activities of Desipramine.
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Desipramine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Desipramine.
Peginterferon alfa-2bThe serum concentration of Desipramine can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineDesipramine may increase the QTc-prolonging activities of Pentamidine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Desipramine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Desipramine.
PerampanelThe risk or severity of adverse effects can be increased when Desipramine is combined with Perampanel.
PerflutrenDesipramine may increase the QTc-prolonging activities of Perflutren.
PergolideThe therapeutic efficacy of Pergolide can be decreased when used in combination with Desipramine.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Desipramine.
PerindoprilThe serum concentration of Desipramine can be increased when it is combined with Perindopril.
PermethrinThe metabolism of Permethrin can be decreased when combined with Desipramine.
PerospironeThe risk or severity of adverse effects can be increased when Desipramine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Desipramine is combined with Perphenazine.
PethidineThe metabolism of Pethidine can be decreased when combined with Desipramine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Desipramine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Desipramine.
PhenelzinePhenelzine may increase the serotonergic activities of Desipramine.
PhenelzineThe risk or severity of adverse effects can be increased when Desipramine is combined with Phenelzine.
PhenforminThe metabolism of Phenformin can be decreased when combined with Desipramine.
PhenindioneDesipramine may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the serotonergic activities of Desipramine.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Desipramine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Desipramine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Desipramine.
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Desipramine.
PhenprocoumonDesipramine may increase the anticoagulant activities of Phenprocoumon.
PhentermineDesipramine may increase the stimulatory activities of Phentermine.
PhenylephrineDesipramine may increase the vasopressor activities of Phenylephrine.
PhenylpropanolamineThe therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Desipramine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Desipramine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Desipramine.
PhosphoramidonThe serum concentration of Desipramine can be increased when it is combined with Phosphoramidon.
PimozideThe risk or severity of adverse effects can be increased when Desipramine is combined with Pimozide.
PindololThe metabolism of Pindolol can be decreased when combined with Desipramine.
PipamperoneThe risk or severity of adverse effects can be increased when Desipramine is combined with Pipamperone.
PiperazineThe metabolism of Piperazine can be decreased when combined with Desipramine.
PipotiazineThe risk or severity of adverse effects can be increased when Desipramine is combined with Pipotiazine.
PirbuterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Pirbuterol.
PirlindolePirlindole may increase the serotonergic activities of Desipramine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Desipramine.
PivhydrazinePivhydrazine may increase the serotonergic activities of Desipramine.
PizotifenThe risk or severity of adverse effects can be increased when Desipramine is combined with Pizotifen.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Desipramine.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Desipramine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Desipramine.
PramipexoleDesipramine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Desipramine.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Desipramine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Desipramine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Desipramine.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Desipramine.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Desipramine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Desipramine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Desipramine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Desipramine.
PrimaquineDesipramine may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Desipramine.
PrinomastatThe serum concentration of Desipramine can be increased when it is combined with Prinomastat.
ProcainamideThe metabolism of Procainamide can be decreased when combined with Desipramine.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Desipramine.
ProcarbazineThe risk or severity of adverse effects can be increased when Desipramine is combined with Procarbazine.
ProcaterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Procaterol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Desipramine is combined with Prochlorperazine.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Desipramine.
PromazineThe risk or severity of adverse effects can be increased when Desipramine is combined with Promazine.
PromazineThe metabolism of Desipramine can be decreased when combined with Promazine.
PromethazineThe metabolism of Promethazine can be decreased when combined with Desipramine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Desipramine.
PropafenoneThe serum concentration of Desipramine can be increased when it is combined with Propafenone.
PropafenoneDesipramine may increase the QTc-prolonging activities of Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Desipramine.
PropericiazineThe risk or severity of adverse effects can be increased when Desipramine is combined with Propericiazine.
PropofolThe metabolism of Propofol can be decreased when combined with Desipramine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Desipramine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Desipramine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Desipramine.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Desipramine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Desipramine.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Desipramine.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Desipramine.
PseudoephedrineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Desipramine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Desipramine.
QuetiapineThe risk or severity of adverse effects can be increased when Desipramine is combined with Quetiapine.
QuinaprilThe serum concentration of Desipramine can be increased when it is combined with Quinapril.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Desipramine.
QuinidineThe metabolism of Desipramine can be decreased when combined with Quinidine.
QuinineThe serum concentration of Quinine can be increased when it is combined with Desipramine.
QuinineThe metabolism of Desipramine can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Desipramine.
RamiprilThe serum concentration of Desipramine can be increased when it is combined with Ramipril.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Desipramine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Desipramine.
RanolazineThe metabolism of Desipramine can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the serotonergic activities of Desipramine.
RasagilineThe risk or severity of adverse effects can be increased when Desipramine is combined with Rasagiline.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Desipramine.
RemikirenThe serum concentration of Desipramine can be increased when it is combined with Remikiren.
RemoxiprideThe risk or severity of adverse effects can be increased when Desipramine is combined with Remoxipride.
repinotanThe metabolism of repinotan can be decreased when combined with Desipramine.
ReserpineThe risk or severity of adverse effects can be increased when Desipramine is combined with Reserpine.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Desipramine.
RifampicinThe metabolism of Desipramine can be increased when combined with Rifampicin.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Desipramine.
RisperidoneThe therapeutic efficacy of Risperidone can be decreased when used in combination with Desipramine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Desipramine.
RitodrineThe risk or severity of adverse effects can be increased when Desipramine is combined with Ritodrine.
RitonavirThe serum concentration of Desipramine can be increased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Desipramine can be increased when it is combined with Rivaroxaban.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Desipramine.
RolapitantThe metabolism of Desipramine can be decreased when combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Desipramine.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Desipramine.
RopiniroleDesipramine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Desipramine can be decreased when combined with Ropinirole.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Desipramine.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Desipramine.
RotigotineDesipramine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Desipramine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Desipramine.
SafrazineSafrazine may increase the serotonergic activities of Desipramine.
SalbutamolThe risk or severity of adverse effects can be increased when Desipramine is combined with Salbutamol.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Desipramine.
SalmeterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Salmeterol.
SaquinavirThe serum concentration of Desipramine can be increased when it is combined with Saquinavir.
SaquinavirDesipramine may increase the QTc-prolonging activities of Saquinavir.
SaxagliptinThe serum concentration of Desipramine can be increased when it is combined with Saxagliptin.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Desipramine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Desipramine.
SelegilineSelegiline may increase the serotonergic activities of Desipramine.
SelegilineThe metabolism of Selegiline can be decreased when combined with Desipramine.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Desipramine.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Desipramine.
SertindoleThe risk or severity of adverse effects can be increased when Desipramine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Desipramine is combined with Sertraline.
SertralineThe metabolism of Desipramine can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Desipramine.
SildenafilThe metabolism of Sildenafil can be decreased when combined with Desipramine.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Desipramine.
SimeprevirThe serum concentration of Desipramine can be increased when it is combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Desipramine.
SitagliptinThe serum concentration of Desipramine can be increased when it is combined with Sitagliptin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Desipramine.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Desipramine.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Desipramine.
SotalolDesipramine may increase the QTc-prolonging activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Desipramine.
SparteineThe metabolism of Sparteine can be decreased when combined with Desipramine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Desipramine.
SpiraprilThe serum concentration of Desipramine can be increased when it is combined with Spirapril.
St. John's WortThe metabolism of Desipramine can be increased when combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Desipramine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Desipramine.
SulfisoxazoleDesipramine may increase the QTc-prolonging activities of Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Desipramine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Desipramine.
SuvorexantThe risk or severity of adverse effects can be increased when Desipramine is combined with Suvorexant.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Desipramine.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Desipramine.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Desipramine.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Desipramine.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Desipramine.
TasimelteonThe risk or severity of adverse effects can be increased when Desipramine is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Desipramine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Desipramine.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Desipramine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Desipramine is combined with Tedizolid Phosphate.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Desipramine.
TelaprevirThe serum concentration of Desipramine can be increased when it is combined with Telaprevir.
TelavancinDesipramine may increase the QTc-prolonging activities of Telavancin.
TelithromycinDesipramine may increase the QTc-prolonging activities of Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Desipramine.
TemocaprilThe serum concentration of Desipramine can be increased when it is combined with Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Desipramine.
TenofovirThe metabolism of Desipramine can be decreased when combined with Tenofovir.
TerbinafineThe metabolism of Desipramine can be decreased when combined with Terbinafine.
TerbutalineThe risk or severity of adverse effects can be increased when Desipramine is combined with Terbutaline.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Desipramine.
TeriflunomideThe serum concentration of Desipramine can be decreased when it is combined with Teriflunomide.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Desipramine.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Desipramine.
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Desipramine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Desipramine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Desipramine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Desipramine.
ThalidomideDesipramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Desipramine.
TheophyllineThe metabolism of Desipramine can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Desipramine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Desipramine.
ThioproperazineThe risk or severity of adverse effects can be increased when Desipramine is combined with Thioproperazine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Desipramine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Desipramine.
ThiorphanThe serum concentration of Desipramine can be increased when it is combined with Thiorphan.
ThiothixeneThe risk or severity of adverse effects can be increased when Desipramine is combined with Thiothixene.
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Desipramine.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Desipramine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Desipramine.
TiclopidineThe metabolism of Desipramine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Desipramine.
TimololThe serum concentration of Timolol can be increased when it is combined with Desipramine.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Desipramine.
TipranavirThe serum concentration of Desipramine can be increased when it is combined with Tipranavir.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Desipramine.
TizanidineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Desipramine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Desipramine.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Desipramine.
ToloxatoneToloxatone may increase the serotonergic activities of Desipramine.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Desipramine.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Desipramine.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Desipramine.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Desipramine.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Desipramine.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Desipramine.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Desipramine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Desipramine.
TrandolaprilThe serum concentration of Desipramine can be increased when it is combined with Trandolapril.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Desipramine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Desipramine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineTranylcypromine may increase the serotonergic activities of Desipramine.
TranylcypromineThe risk or severity of adverse effects can be increased when Desipramine is combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Desipramine.
TrazodoneThe risk or severity of adverse effects can be increased when Desipramine is combined with Trazodone.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Desipramine.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Desipramine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Desipramine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Desipramine is combined with Triflupromazine.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Desipramine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Desipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Desipramine.
UbenimexThe serum concentration of Desipramine can be increased when it is combined with Ubenimex.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Desipramine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Desipramine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Desipramine.
VandetanibDesipramine may increase the QTc-prolonging activities of Vandetanib.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Desipramine.
VemurafenibThe serum concentration of Desipramine can be increased when it is combined with Vemurafenib.
VemurafenibDesipramine may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Desipramine.
VenlafaxineThe metabolism of Desipramine can be decreased when combined with Venlafaxine.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Desipramine.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Desipramine.
VilanterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Vilanterol.
VilazodoneThe risk or severity of adverse effects can be increased when Desipramine is combined with Vilazodone.
VildagliptinThe serum concentration of Desipramine can be increased when it is combined with Vildagliptin.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Desipramine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Desipramine.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Desipramine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Desipramine.
VoriconazoleThe metabolism of Desipramine can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Desipramine is combined with Vortioxetine.
WarfarinDesipramine may increase the anticoagulant activities of Warfarin.
XimelagatranThe serum concentration of Desipramine can be increased when it is combined with Ximelagatran.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Desipramine.
XylometazolineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Desipramine.
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Desipramine.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Desipramine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Desipramine.
ZiconotideThe risk or severity of adverse effects can be increased when Desipramine is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Desipramine.
ZimelidineThe risk or severity of adverse effects can be increased when Desipramine is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Desipramine is combined with Ziprasidone.
ZiprasidoneThe metabolism of Desipramine can be decreased when combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Desipramine.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Desipramine.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Desipramine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Desipramine.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Desipramine.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Desipramine.
ZotepineThe risk or severity of adverse effects can be increased when Desipramine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Desipramine is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation, limit caffeine intake.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Zavosh A, Schaefer J, Ferrel A, Figlewicz DP: Desipramine treatment decreases 3H-nisoxetine binding and norepinephrine transporter mRNA in SK-N-SHSY5Y cells. Brain Res Bull. 1999 Jul 1;49(4):291-5. [PubMed:10424850 ]
  2. Weinshenker D, White SS, Javors MA, Palmiter RD, Szot P: Regulation of norepinephrine transporter abundance by catecholamines and desipramine in vivo. Brain Res. 2002 Aug 16;946(2):239-46. [PubMed:12137927 ]
  3. Bryan-Lluka LJ, Bonisch H, Lewis RJ: chi-Conopeptide MrIA partially overlaps desipramine and cocaine binding sites on the human norepinephrine transporter. J Biol Chem. 2003 Oct 10;278(41):40324-9. Epub 2003 Jul 1. [PubMed:12837768 ]
  4. Zhu MY, Kyle PB, Hume AS, Ordway GA: The persistent membrane retention of desipramine causes lasting inhibition of norepinephrine transporter function. Neurochem Res. 2004 Feb;29(2):419-27. [PubMed:15002740 ]
  5. Ordway GA, Jia W, Li J, Zhu MY, Mandela P, Pan J: Norepinephrine transporter function and desipramine: residual drug effects versus short-term regulation. J Neurosci Methods. 2005 Apr 30;143(2):217-25. Epub 2004 Dec 30. [PubMed:15814154 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Holmes A, Yang RJ, Murphy DL, Crawley JN: Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter. Neuropsychopharmacology. 2002 Dec;27(6):914-23. [PubMed:12464448 ]
  2. Gould GG, Altamirano AV, Javors MA, Frazer A: A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters. Biol Psychiatry. 2006 Mar 1;59(5):408-14. Epub 2005 Sep 2. [PubMed:16140280 ]
  3. Zhou L, Huang KX, Kecojevic A, Welsh AM, Koliatsos VE: Evidence that serotonin reuptake modulators increase the density of serotonin innervation in the forebrain. J Neurochem. 2006 Jan;96(2):396-406. Epub 2005 Nov 21. [PubMed:16300628 ]
  4. Hoffman AF, Gerhardt GA: In vivo electrochemical studies of dopamine clearance in the rat substantia nigra: effects of locally applied uptake inhibitors and unilateral 6-hydroxydopamine lesions. J Neurochem. 1998 Jan;70(1):179-89. [PubMed:9422361 ]
  5. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Matsumoto K, Ojima K, Ohta H, Watanabe H: Beta 2- but not beta 1-adrenoceptors are involved in desipramine enhancement of aggressive behavior in long-term isolated mice. Pharmacol Biochem Behav. 1994 Sep;49(1):13-8. [PubMed:7816863 ]
  2. Sapena R, Morin D, Zini R, Morin C, Tillement JP: Desipramine treatment differently down-regulates beta-adrenoceptors of freshly isolated neurons and astrocytes. Eur J Pharmacol. 1996 Apr 4;300(1-2):159-62. [PubMed:8741184 ]
  3. Abadie C, Foucart S, Page P, Nadeau R: Modulation of noradrenaline release from isolated human atrial appendages. J Auton Nerv Syst. 1996 Dec 14;61(3):269-76. [PubMed:8988485 ]
  4. Prenner L, Sieben A, Zeller K, Weiser D, Haberlein H: Reduction of high-affinity beta2-adrenergic receptor binding by hyperforin and hyperoside on rat C6 glioblastoma cells measured by fluorescence correlation spectroscopy. Biochemistry. 2007 May 1;46(17):5106-13. Epub 2007 Apr 7. [PubMed:17417877 ]
  5. Osadchii OE, Woodiwiss AJ, Deftereos D, Norton GR: Temporal changes in myocardial adrenergic regulation with the progression to pump dysfunction after chronic beta-adrenoreceptor activation in rats. Pflugers Arch. 2007 Nov;455(2):251-60. Epub 2007 Jun 9. [PubMed:17558518 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Sapena R, Morin D, Zini R, Morin C, Tillement JP: Desipramine treatment differently down-regulates beta-adrenoceptors of freshly isolated neurons and astrocytes. Eur J Pharmacol. 1996 Apr 4;300(1-2):159-62. [PubMed:8741184 ]
  2. Burgi S, Baltensperger K, Honegger UE: Antidepressant-induced switch of beta 1-adrenoceptor trafficking as a mechanism for drug action. J Biol Chem. 2003 Jan 10;278(2):1044-52. Epub 2002 Oct 21. [PubMed:12393876 ]
  3. Matsumoto K, Ojima K, Ohta H, Watanabe H: Beta 2- but not beta 1-adrenoceptors are involved in desipramine enhancement of aggressive behavior in long-term isolated mice. Pharmacol Biochem Behav. 1994 Sep;49(1):13-8. [PubMed:7816863 ]
  4. Samnick S, Scheuer C, Munks S, El-Gibaly AM, Menger MD, Kirsch CM: Technetium-99m labeled 1-(4-fluorobenzyl)-4-(2-mercapto-2-methyl-4-azapentyl)-4-(2-mercapto-2-methylprop ylamino)-piperidine and iodine-123 metaiodobenzylguanidine for studying cardiac adrenergic function: a comparison of the uptake characteristics in vascular smooth muscle cells and neonatal cardiac myocytes, and an investigation in rats. Nucl Med Biol. 2004 May;31(4):511-22. [PubMed:15093822 ]
  5. Mudunkotuwa NT, Horton RW: Desipramine administration in the olfactory bulbectomized rat: changes in brain beta-adrenoceptor and 5-HT2A binding sites and their relationship to behaviour. Br J Pharmacol. 1996 Apr;117(7):1481-6. [PubMed:8730743 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sphingomyelin phosphodiesterase activity
Specific Function:
Converts sphingomyelin to ceramide. Also has phospholipase C activities toward 1,2-diacylglycerolphosphocholine and 1,2-diacylglycerolphosphoglycerol. Isoform 2 and isoform 3 have lost catalytic activity.
Gene Name:
SMPD1
Uniprot ID:
P17405
Molecular Weight:
69751.3 Da
References
  1. Testai FD, Landek MA, Dawson G: Regulation of sphingomyelinases in cells of the oligodendrocyte lineage. J Neurosci Res. 2004 Jan 1;75(1):66-74. [PubMed:14689449 ]
  2. Kolzer M, Werth N, Sandhoff K: Interactions of acid sphingomyelinase and lipid bilayers in the presence of the tricyclic antidepressant desipramine. FEBS Lett. 2004 Feb 13;559(1-3):96-8. [PubMed:14960314 ]
  3. Erdreich-Epstein A, Tran LB, Cox OT, Huang EY, Laug WE, Shimada H, Millard M: Endothelial apoptosis induced by inhibition of integrins alphavbeta3 and alphavbeta5 involves ceramide metabolic pathways. Blood. 2005 Jun 1;105(11):4353-61. Epub 2005 Feb 10. [PubMed:15705795 ]
  4. Zeidan YH, Pettus BJ, Elojeimy S, Taha T, Obeid LM, Kawamori T, Norris JS, Hannun YA: Acid ceramidase but not acid sphingomyelinase is required for tumor necrosis factor-{alpha}-induced PGE2 production. J Biol Chem. 2006 Aug 25;281(34):24695-703. Epub 2006 Jun 27. [PubMed:16803890 ]
  5. Hurwitz R, Ferlinz K, Sandhoff K: The tricyclic antidepressant desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts. Biol Chem Hoppe Seyler. 1994 Jul;375(7):447-50. [PubMed:7945993 ]
  6. Kornhuber J, Tripal P, Reichel M, Muhle C, Rhein C, Muehlbacher M, Groemer TW, Gulbins E: Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications. Cell Physiol Biochem. 2010;26(1):9-20. doi: 10.1159/000315101. Epub 2010 May 18. [PubMed:20502000 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Sawynok J, Esser MJ, Reid AR: Peripheral antinociceptive actions of desipramine and fluoxetine in an inflammatory and neuropathic pain test in the rat. Pain. 1999 Aug;82(2):149-58. [PubMed:10467920 ]
  2. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein group
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Components:
NameUniProt IDDetails
Alpha-1A adrenergic receptorP35348 Details
Alpha-1B adrenergic receptorP35368 Details
Alpha-1D adrenergic receptorP25100 Details
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  3. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  3. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Palvimaki EP, Roth BL, Majasuo H, Laakso A, Kuoppamaki M, Syvalahti E, Hietala J: Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology (Berl). 1996 Aug;126(3):234-40. [PubMed:8876023 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol.
Components:
NameUniProt IDDetails
Alpha-2A adrenergic receptorP08913 Details
Alpha-2B adrenergic receptorP18089 Details
Alpha-2C adrenergic receptorP18825 Details
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Lewis DF, Modi S, Dickins M: Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82. [PubMed:11996013 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
  2. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880 ]
  2. Arndt P, Volk C, Gorboulev V, Budiman T, Popp C, Ulzheimer-Teuber I, Akhoundova A, Koppatz S, Bamberg E, Nagel G, Koepsell H: Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1. Am J Physiol Renal Physiol. 2001 Sep;281(3):F454-68. [PubMed:11502595 ]
  3. Grundemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H: Drug excretion mediated by a new prototype of polyspecific transporter. Nature. 1994 Dec 8;372(6506):549-52. [PubMed:7990927 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, Baumann C, Lang F, Busch AE, Koepsell H: Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81. [PubMed:9260930 ]
  2. Arndt P, Volk C, Gorboulev V, Budiman T, Popp C, Ulzheimer-Teuber I, Akhoundova A, Koppatz S, Bamberg E, Nagel G, Koepsell H: Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1. Am J Physiol Renal Physiol. 2001 Sep;281(3):F454-68. [PubMed:11502595 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Toxin transporter activity
Specific Function:
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name:
SLC22A3
Uniprot ID:
O75751
Molecular Weight:
61279.485 Da
References
  1. Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, Leibach FH, Ganapathy V: Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol. 2000 Sep;279(3):F449-58. [PubMed:10966924 ]
  2. Kekuda R, Prasad PD, Wu X, Wang H, Fei YJ, Leibach FH, Ganapathy V: Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. J Biol Chem. 1998 Jun 26;273(26):15971-9. [PubMed:9632645 ]
  3. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V: Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem. 1998 Dec 4;273(49):32776-86. [PubMed:9830022 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Also relative uptake activity ratio of carnitine to TEA is 11.3.
Gene Name:
SLC22A5
Uniprot ID:
O76082
Molecular Weight:
62751.08 Da
References
  1. Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ, Ganapathy V: Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther. 1999 Sep;290(3):1482-92. [PubMed:10454528 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Relative uptake activity ratio of carnitine to TEA is 1.78. A key substrate of this transporter seems to be ergothioneine (ET).
Gene Name:
SLC22A4
Uniprot ID:
Q9H015
Molecular Weight:
62154.48 Da
References
  1. Wu X, George RL, Huang W, Wang H, Conway SJ, Leibach FH, Ganapathy V: Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. Biochim Biophys Acta. 2000 Jun 1;1466(1-2):315-27. [PubMed:10825452 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23